
GI Fellow & incoming AEF @WVU_GI | MRCP(UK) | Husband | Dad 🇪🇬🇶🇦🇺🇸 Pubs: https://teapawt.org/t.co/kfqEbUiOcH
Morgantown, WV
Joined January 2021
- Tweets1.5K
- Following1.8K
- Followers2.4K
- Likes4.9K
Pinned Tweet
Excited to share that I matched at my #1 choice for AEF and will be staying at @WVU_GI! Grateful to continue learning under the mentorship of Drs. @ShyamTMD, @shailsingh, and @SkipKrafftMD. Thanks to Dr. @mdmarathon, Dr. Gayam, Dr. Elhanafi and my wife & family for their support!
Khaled Elfert retweeted
Dr. @HamawyForNJ becomes the second-ever Egyptian-American to serve in Congress.
Hamawy treated the wounded on 9/11, served as a US Army physician, and took part on a volunteer mission of doctors in Gaza in May 2024, in which he performed 120 surgeries.
Khaled Elfert retweeted
Ileum intubation:
9 to 11 o'clock: pull back, big wheel up, torque counterclockwise, air, big wheel down a bit.
6 to 7 o'clock: pull back slowly, big wheel down, air, big wheel down a bit, slight torque right.
Use water. Push gently.
Which is harder?
Khaled Elfert retweeted
HIBSAGO (bepirovirsen) is now FDA-approved for chronic hep B. I made a one-page clinic protocol: who qualifies, dosing, labs, the week 12 & 48 decisions, and hold/stop rules.
qaddodi.github.io/hibsago-pr…
@GSK @IonisPharma @AASLDtweets @EASLnews @HepBFoundation #LiverTwitter #HepB
Khaled Elfert retweeted
Ready to Explore the Path to GI Fellowship in the US !?
*Our Episode is Now on Youtube*🎙
youtu.be/aanGONl2b-s?si…
Hear directly from our panel of GI physicians as they share their journeys and practical advice to help you navigate the path to Adult GI Fellowship in the US 🇺🇸
Khaled Elfert retweeted
The guidelines for primary biliary cholangitis (#PBC) were just updated in a joint AASLD/AGA effort & published simultaneously in @HEP_Journal. Here is how it compares with the 2018 AASLD guidance & its 2021 update:
1. UDCA 13–15 mg/kg/day remains first-line therapy with higher doses not recommended. UDCA should continue even when patients do not achieve their treatment targets given the survival benefit.
2. For diagnosis, suspected PBC with negative antimitochondrial antibodies (AMA) should be tested for anti-sp100 and anti-gp210 BEFORE liver biopsy, & a positive test obviates the need for biopsy (unless AIH overlap/alternative Dx is suspected). This was already included in the 2018 guidance & now is formally graded. Fun fact: these were a question in the @AmCollegeGastro GI Jeopardy competition, 2026.
3. Liver stiffness measurement is now formally recommended for PBC patients. This is a new recommendationnew recommendations. The utopic goal of PBC patient is to have a liver stiffness measurement (LSM) below 10 kPa, if possible. Again, utopic, rather than actual goal.
Related fun fact: Patients with PBC can develop severe portal hypertension complications without a significant elevation in their stiffness measurement due to the significant presinosoidal component of the disease.
4. Targets of therapy are to be assessed in the window of 6-12 months after treatment, and the lowest acceptable goal is a reduction of Alkaline phosphatase (ALP) to <1.5 the upper limit of normal after the first year of treatment (with normal bilirubin). The ideal goal is normalization of the ALP, not always attainable. In higher-risk patients, specifically with LSM ≥10 kPa, you should strive to achieve this target. This is also how stiffness measurement can change our approach now.
5. THE MAJOR UPDATE: PPAR agonists (elafibranor & seladelpar) are now formally recommended as second-line therapy, & obeticholic acid is NO LONGER part of the US treatment algorithm (following withdrawal of its FDA approval in 2025).
6. Linerixibat is a now an option for severe pruritis not responding to the first or second line agents. This is a new recommendation.
7. UDCA prophylaxis AFTER liver transplantation is now explicitly recommended to reduce recurrent PBC (~20% by 5 years and ~50% by 20 years) & graft failure.
#GITwitter #MedTwitter #MedEd #AASLD #AASLDTweets #Hepatology @AmerGastroAssn @AASLDtweets
Khaled Elfert retweeted
🚀 Mastering the Adult GI Fellowship Pathway in the U.S.!
Join EMG for an exclusive live panel with leaders from Univ. of Tennessee, WVU, Cleveland Clinic FL & Cook County Chicago! 🩺✨
📅 Sat, Oct 24 | ⏰ 11 AM EST / 6 PM Cairo
💻 Live on Zoom (Q&A included)
Don't miss out!👇
Khaled Elfert retweeted
12 years after its previous update, @ASGEendoscopy has released its 2026 lower GI bleeding guideline & is now in press in @GIE_Journal. Here's the key shifts from 2014 guidelines:
1. Urgent colonoscopy within 24hrs is NO LONGER emphasized. Colonoscopy is now recommended only for hemodynamically stable patients who can tolerate a full bowel preparation, irrespective of the timing. This matches other national society guidelines where the role of urgent colonoscopy has been already de-emphasized.
2. Hemodynamic instability favors contrast CT/CTA, & the subsequent management is IR-guided. This corresponds to interventional radiology guidelines (SAR) & takes the ball of the acute LGIB to the IR court. This still holds true even in the setting of "modest" acute or chronic kidney disease. "Modest" is undefined.
4. Band ligation is recommended as first line for RIGHT sided diverticulae due to the lower recurrent bleeding. Notably, the risk of perforation with banding is real & the document reports panel disagreement & split opinions regarding this point. The ASGE recommends using a colonoscope ligator & against a gastroscope ligator. Fortunately or unfortunately, colonoscope band ligators are exceedingly rare in the United States, & hence a lower chance of gastroenterologist to debate this point.
5. Clip closure is recommended over band ligation in the LEFT sided diverticulae. In the left colon, clips and bands are equal in efficacy, & in the absence of a clear benefit, taking the perforation risk associated with banding was not worth.
6. Direct clipping of the vessel is suggested over indirect (zipper) closure. This is a new recommendation & is driven by the lower rebleeding rate (nothing to do with diverticulitis).
#GITwitter #MedTwitter #MedEd #Endoscopy
Khaled Elfert retweeted
That's a wrap! #ACG2026
Highlights 👏🏻
▪️Competed in EndoTitans as one of the top 6 third-year GI fellows nationally
▪️SCOPY Award honorable mention for our CRC campaign
▪️Abstract reviewer and a poster judge
▪️Educational affairs committee meeting
▪️3 projects presented
▪️Caught up with old friends and made new ones
Grateful for this community🤩 #GITwitter
@AmCollegeGastro @FarahKhraisat98 @MENAGastro @ScrubsNHeels @WomenInGI @mdmanatee
Khaled Elfert retweeted
Icing 🥶🧊 the papilla to decrease post-ERCP pancreatitis 😖 - ⬇️ PEP rates in ERCPs with inadvertent PD cannulation and further analysis pending. Great work and low cost initiative! @UCLAGIHep @DannyIssaMD @UTSWGastroHep @TomTielleman
Khaled Elfert retweeted
One in four US doctors trained abroad. A viral thread calls that a scandal. It is not. It is the only reason hospitals in the Bronx and rural Alabama have doctors at all. 🧵
Khaled Elfert retweeted
Again, the vast majority of this is not H1B fraud.
What you’re looking at is a cherry-picked list of community programs that are forced to accept IMGs because U.S. medical schools train 15,000 less medical graduates compared to available residency spots. In 2025, for example, there was 52,577 American college students who applied to medical school and only 22,262 were accepted. BUT, in 2025 there was also ~40,993 residency slots. When you add U.S. MDs and U.S. DOs applying to residency in 2025 you got roughly 27,498. That’s 13,495 short.
Who fills them? Two: U.S. IMGs (American international medical graduates) and non-U.S. IMGs (those are the “foreign” doctors you’re referring to).
Now, where do these IMGs match? Overwhelmingly in primary care and rural-suburban programs, which historically are areas US MDs don’t prefer. However, AND THIS IS IMPORTANT: JUST BECAUSE US MDs DONT PREFER IT DOES NOT MEAN THEY WOULDNT DO IT IF THAT WAS THEIR ONLY OPTION. Check charts below.
The evidence shows that 67-85% of US MDs would rather take ANY specialty and program over waiting just one more year to try again.
So what does this all mean?
1. The problem is not IMGs
2. The problem is not residency programs
3. The problem is upstream, at the medical school level. Why do we have ~52,000 Americans trying to get into med school and we turn away 58% of them?
4. IMGs are filling a need in a vacuum we created. Getting rid of IMGs would collapse healthcare in its current state
5. No, it’s not true that “Americans wouldn’t take those jobs anyway.” This is a scapegoat that lacks nuance. The match data is evidence against it. We shouldn’t invent arguments to mask bad policy
6. Bad policy persists only when incentives are involved. So who’s involved is the question you should be asking instead of racially targeting doctors.
7. The truth is we do need a diverse workforce, data shows patient-physician congruence is an important aspect of care management
8. We need to stop screwing over American students
It can all be true. This is a complex issue that’s cemented for 100 years now.
Look at this chart.
These are American residency programs.
Red = foreign resident doctors.
Grey = Americans.
Some hospitals are almost 100% foreign. A lot of these doctors came in on visas. Some have been tied to fake credentials and USMLE cheating scandals.
I pay the premiums. I wait months to be seen. Taxpayer-funded Medicare GME money(over $21 billion a year) is training these foreign doctors instead of Americans.
And I DO NOT even trust these doctors !
Why should we keep funding this?
Khaled Elfert retweeted
𝗕𝗨𝗥𝗦𝗧𝗜𝗡𝗚 𝘁𝗵𝗲 𝗠𝗜𝗦𝗜𝗡𝗙𝗢𝗥𝗠𝗔𝗧𝗜𝗢𝗡 𝗕𝗨𝗕𝗕𝗟𝗘:
This is exactly how misinformation about IMGs gets manufactured.
The claim that IMGs at Rochester General are simply “taking residency jobs from American medical graduates” ignores how the Match actually works. The NRMP algorithm is applicant-proposing: applicants rank programs based on where they want to train, while programs rank applicants they are willing to train.
Look at the data.
At the Same Rochester General, IMG representation varies dramatically by specialty:
Internal Medicine — ~97% IMG
OB/GYN — ~30% IMG
Interventional Radiology — 0% IMG
PM&R — 0% IMG among residents whose medical schools are publicly listed
And only about 6 miles away, University of Rochester/Strong Memorial Internal Medicine is ~2.5% IMG based on its current core resident roster.
Same city.
Same specialty.
Same Match.
RGH IM: ~97% IMG
U of Rochester IM: ~2.5% IMG
Why such a massive difference? Applicant preference is part of the equation. U.S. graduates with competitive applications can rank university-based IM programs offering different academic environments, resources and career opportunities more highly. Community programs can therefore end up with very different applicant and rank-list pools. That is not evidence that RGH deliberately “replaced Americans with foreigners.” The Match outcome reflects both applicant and program preferences.
And notice what happens in a competitive specialty:
RGH Integrated Interventional Radiology is 0% IMG. RGH itself describes IR as a competitive field.
If the hospital were systematically refusing Americans in favor of IMGs, why would its residency composition change so dramatically simply by changing specialties?
Finally, IMG ≠ foreign worker.
IMG describes where someone attended medical school, not their citizenship or visa status.
Calling IMGs “H-1B/J-1 foreign workers” without actually establishing their immigration status is simply unsupported.
The difference is obvious once you understand how residency selection and the Match actually work.
Unfortunately, this is the same cycle of misinformation we saw after the 2026 Residency Match. Instead of focusing on strengthening U.S. healthcare, some are pushing misleading narratives that malign IMGs physicians who make up a substantial part of the U.S. healthcare workforce.
#Match2027 #MedTwitter #USMLE #internalmedicineResidency #H1B
Outstanding presentation about bariatric and metabolic endoscopy by Dr. Singh @shailsingh at the Pennsylvania Society of Gastroenterology meeting. #ESG #TORe #DMR @WVU @wvudeptofmed
Khaled Elfert retweeted
🚨 Hot off the press- Our study compared FCSEMS vs LNSC for malignant esophageal disease - cryodilation showed fewer adverse events with comparable clinical success to stenting.
sciencedirect.com/science/ar…
@GIE_Journal @ShyamTMD @ASGEendoscopy @shailsingh @SkipKrafftMD
Khaled Elfert retweeted
Thanks @UEGJournal for highlighting our study and featuring it in the podcast! 🎙️
👉🏼 We found that GLP-1 RA use in T2DM was associated with a modestly increased risk of gallstones & biliary complications. 💉
📌 Check the podcast here:
bit.ly/4x0N5B0
🟣 #GLP1 receptor agonists are linked to a modest rise in biliary events in #Diabetes
🔸More gallstones/cholecystitis/cholecystectomy at 3 years
🔸No significant increase in pancreatitis or ERCP
🔸Absolute event rates remained low
📖 #OpenAccess 👉 bit.ly/4x0N5B0
Khaled Elfert retweeted
Our very own, Dr Tandon, @TandonKp is moderating the next ACG virtual grand rounds!
ACG Virtual Grand Rounds — Gastro-Esophageal Disorders of the Geriatric Population
w/ Dr. Nicholas Shaheen
Thursday, August 20 at Noon & 8 pm ET
➡️ gi.org/ACGVGR
@nshaheenUNC @TandonKp
Khaled Elfert retweeted
No me había fijado que Nico Williams alcanza a dar la asistencia gracias al empujón que le da Nahuel Molina.
JAJAAJAJJAAJJAJAJAJAJJAJ
Khaled Elfert retweeted
Honored and excited to advance to the EndoTitans 2026 Final Hands-On Competition at #ACG2026!
@AmCollegeGastro
I’m grateful to have finished as one of the top 6 second-year GI fellows selected from 150+ trainees who competed this year.
Looking forward to representing my program (TBHC) in Nashville on October 11. If you’re attending ACG, I’d love to see you there—your support would mean a lot!
@AmerGastroAssn @ASGEendoscopy
@GiResearchClub
#EndoTitans #GITwitter #GIFellow #ACG2026 – at Queens, NY







































